The CEPHEUS trial highlights DVRd's greater treatment durability and tolerability, with more patients remaining on treatment through cycle 36 compared to VRd. Both DVRd and VRd regimens led to ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen alongside bortezomib, lenalidomide, and dexamethasone (VRd), for ...